A Study of Selinexor Monotherapy in Subjects With JAK Inhibitor-naïve Myelofibrosis and Moderate Thrombocytopenia
Recruiting now · Phase 2
Conditions studied: Myelofibrosis, Moderate Thrombocytopenia, Mild Thrombocytopenia
In brief
The main purpose of this study is to evaluate the efficacy of selinexor in JAKi-naïve participants with myelofibrosis (MF) and with normal platelet counts or with mild to moderate thrombocytopenia based on spleen volume reduction (SVR). Additional efficacy and safety parameters will also be assessed during the study.
Key facts
- Study ID
- NCT05980806
- Run by
- Karyopharm Therapeutics Inc
- People needed
- 58
- Starts
- 2024-04-22
- Expected to finish
- 2028-10-01
- Last updated by the study team
- 2026-02-12
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Maryland Oncology Hematology - Independent of SCRI/ US Oncology — Columbia, Maryland, United States (enrolling)
- Weill Cornell Medicine NewYork-Presbyterian — New York, New York, United States (enrolling)
- Duke University — Durham, North Carolina, United States (enrolling)
- Cleveland Clinic — Cleveland, Ohio, United States (enrolling)
- MD Anderson — Houston, Texas, United States (enrolling)
- Huntsman Cancer Institute — Salt Lake City, Utah, United States (enrolling)
- UZ Gent — Ghent, Belgium (enrolling)
- UZ Leuven - Campus Gasthuisberg — Leuven, Belgium (enrolling)
- University Multiprofile Hospital for Active Treatment Sveti George - Base 1 — Plovdiv, Bulgaria (enrolling)
- University Hospital Sv.Ivan Rilski - Sofia — Sofia, Bulgaria (enrolling)
- University Multiprofile Hospital for Active Treatment Aleksandrovska — Sofia, Bulgaria (enrolling)
- Specialized Hospital for Active Treatment of Hematological Diseases - EAD Sofia — Sofia, Bulgaria (enrolling)
- University Multiprofile Hospital for Active Treatment - Prof. Dr. Stoyan Kirkovich AD Department of Clinical Hematology — Stara Zagora, Bulgaria (enrolling)
- Research Institute of the McGill University Health Centre — Montreal, Quebec, Canada (enrolling)
- Fakultní nemocnice Olomouc — Olomouc, Czechia (enrolling)
- Aarhus Universitetshospital — Aarhus N, Central Jutland, Denmark (enrolling)
- Institut Bergonié — Bordeaux, Aquitaine, France (enrolling)
- Centre Hospitalier Lyon-Sud — Pierre-Bénite, Auvergne-Rhône-Alpes, France (enrolling)
- CHU Tours, Hôpital Bretonneau Service d'Hématologie thérapie cellulaire — Tours, Indre-et-Loire, France (enrolling)
- Chu De Nîmes - Institut De Cancérologie Du Gard — Nîmes, Occitanie, France (enrolling)
- Centre Hospitalier Universitaire d'Angers — Angers, Pays de la Loire Region, France (enrolling)
- Hôpital Saint-Louis — Paris, France (enrolling)
- Hôpital Cochin — Paris, France (enrolling)
- Centre Hospitalier Universitaire de Saint-Etienne — Saint-Priest-en-Jarez, France (enrolling)
- City of Hope - Duarte Main Site — Duarte, California, United States (enrolling)
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.